Business Context and Reporting Period
This Form 8-K Current Report was filed by Palisade Bio, Inc. on May 10, 2024, covering events that occurred on May 7, 2024. The filing primarily addresses corporate governance changes regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on personnel appointments rather than financial performance.
Material Changes
The material change reported is the appointment of Margery Fischbein to the Board of Directors. As of the effective date, the Board consists of four acting directors. Ms. Fischbein has been determined to be independent and has been appointed to the Audit Committee.
Guidance, Outlook, and Compensation Details
The filing contains no guidance, outlook, or management commentary regarding future financial performance or risks. However, it details the compensatory arrangements for the new director:
- Cash Compensation: Ms. Fischbein will participate in the Company's standard non-executive board compensation plan.
- Equity Grant: In lieu of standard equity grants, she received an option to purchase 1,000 shares of common stock.
- Option Terms: The option has a 10-year term, an exercise price of $7.90 per share, and vests in equal quarterly installments over three years.
- Source: The option was issued from the Company's 2021 Equity Incentive Plan.
Investor Verification Checklist
- Verify the independence status of Margery Fischbein under Nasdaq Rule 5605(a)(2).
- Confirm the total number of directors currently serving on the Board (reported as four).
- Review the definitive proxy statement filed on April 21, 2023, for details on the standard non-executive board cash compensation plan.
- Check the vesting schedule and exercise price ($7.90) of the 1,000-share option granted to Ms. Fischbein.